Vaccine for urinary tract infection is NanoBio's goal after getting University of Michigan license
File photo by Robert Ramey | AnnArbor.com's Business Review
NanoBio plans to take the antigen, which was developed by U-M scientists, and combine it with a nanoemulsion-based technology that NanoBio is already leveraging to create other new therapies.
Scientists expect development of a vaccine to take at least 10 years.
The deal tightens the already close relationship between NanoBio and U-M, which collaborate on several projects. Baker is also director of U-M’s Michigan Nanotechnology Institute for Medicine and Biological Studies.
The deal also comes as NanoBio is boosting its commitment to Ann Arbor. The company recently added four laboratories and office space at its headquarters on Green Road.
NanoBio is backed by deep-pocketed venture capital investors and a lucrative licensing deal from GlaxoSmithKline. The company employs more than 20 workers in Ann Arbor.